Product Description
Prednicarbate is a synthetic nonhalogenated moderate to high potency corticosteroid. It is rapidly metabolised during skin permeation to prednisolone. Prednicarbate is indicated for relief of inflammation and pruritus associated with corticosteroid-responsive dermatological disorders such as dermatitis (eczema) [including atopic dermatitis] and psoriasis and can be used in children and elderly patients. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18020557/)
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Canada | Chile | Colombia | Croatia | Denmark | Dominican Republic | Ecuador | Egypt | Germany | India | Indonesia | Italy | Jordan | Korea | Lebanon | Mexico | Pakistan | Peru | Philippines | Slovenia | Spain | Sweden | Switzerland | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|